Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Restructuring Costs (2018 - 2021)

Ironwood Pharmaceuticals' Restructuring Costs history spans 4 years, with the latest figure at -$73000.0 for Q3 2021.

  • For Q3 2021, Restructuring Costs fell 105.93% year-over-year to -$73000.0; the TTM value through Sep 2021 reached $14.1 million, up 1264.22%, while the annual FY2020 figure was $15.4 million, 324.92% up from the prior year.
  • Restructuring Costs for Q3 2021 was -$73000.0 at Ironwood Pharmaceuticals, up from -$282000.0 in the prior quarter.
  • Across five years, Restructuring Costs topped out at $14.2 million in Q4 2020 and bottomed at -$282000.0 in Q2 2021.
  • The 4-year median for Restructuring Costs is $705000.0 (2018), against an average of $2.6 million.
  • The largest annual shift saw Restructuring Costs surged 44318.75% in 2020 before it crashed 105.93% in 2021.
  • A 4-year view of Restructuring Costs shows it stood at $705000.0 in 2018, then plummeted by 104.54% to -$32000.0 in 2019, then soared by 44318.75% to $14.2 million in 2020, then crashed by 100.52% to -$73000.0 in 2021.
  • Per Business Quant, the three most recent readings for IRWD's Restructuring Costs are -$73000.0 (Q3 2021), -$282000.0 (Q2 2021), and $311000.0 (Q1 2021).